izalontamab brengitecan (Bristol Myers Squibb)

Izalontamab brengitecan (BMS-986340) is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting Trophoblast cell-surface antigen 2 (TROP2) conjugated to a camptothecin-derivative payload (a topoisomerase I inhibitor) via a site-specific, protease-cleavable linker. Developed by Bristol Myers Squibb through a license agreement with LegoChem Biosciences, the drug utilizes the ConjuAll platform to achieve a high drug-to-antibody ratio (DAR) and improved stability. TROP2 is a transmembrane glycoprotein frequently overexpressed in various solid tumors, including urothelial, lung, and breast cancers, where it promotes tumor cell proliferation and survival. Upon binding to TROP2, the ADC is internalized, and the cytotoxic payload is released within the lysosomal compartment, leading to DNA damage and apoptosis. It is currently being evaluated in Phase 2/3 clinical trials for patients with metastatic or unresectable urothelial cancer who have progressed after prior immunotherapy.

Other names

izalontamab-brengitecan